New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

References

• National Cancer InstituteSurveillance epidemiology and end results: cancer of the stomach URL: http://seer.cancer.gov/statfacts/html/stomach.html. Accessed October 2010.
   Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against her-2 for metastatic breast cancer that expresses her-2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• GschwindAFischerOMUllrichAThe discovery of receptor tyrosine kinases: targets for cancer therapyNat Rev Cancer20044536137015122207
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: revisiting ERBB2 and discovering ERBB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• WorthylakeROpreskoLKWileyHSErbB2 amplification inhibits down-regulation and induces constitutive activation of both ErbB2 and epidermal growth factor receptorsJ Biol Chem1999274138865887410085130
   PubMed Web of Science ®Google Scholar
• GravalosCJimenoAHER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnn Oncol20081991523152918441328
   PubMed Web of Science ®Google Scholar
• YamamotoTIkawaSAkiyamaTSimilarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature198631960502302343003577
   PubMed Web of Science ®Google Scholar
• YonemuraYNinomiyaIYamaguchiAEvaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancerCancer Res1991513103410381670998
   PubMed Web of Science ®Google Scholar
• GrabshHSivakumarSGraySGabbertHEMulllerWHER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent case seriesCell Oncol2010321–2576520208134
   PubMed Web of Science ®Google Scholar
• HofmannMStossOShiDAssessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology200852779780518422971
   PubMed Web of Science ®Google Scholar
• TannerMHollmenMJunttilaTTAmplification of HER2 in gastric carcinoma: associated with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnn Onc2005162273278
   PubMed Web of Science ®Google Scholar
• BangYVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• ZhangXLYangYSXuDPComparative study on overexpression of HER2/neu and HER3 in gastric cancerWorld J Surg200933102112211819636613
   PubMed Web of Science ®Google Scholar
• MatsubaraJYamadaYHirashimaYImpact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancerClin Cancer Res200814103022302918483367
   PubMed Web of Science ®Google Scholar
• MizutaniTOndaMTokunagaAYamanakaNSugisakiYRelationship of C-erbB-2 protein expression and gene amplication to invasion and metastasis in human gastric cancerCancer1993727208320888397058
   PubMed Web of Science ®Google Scholar
• TateishiMTodaTMinamisonoYNagasakiSClinicopathological significance of c-erbB-2 protein expression in human gastric carcinomaJ Surg Onc1992494209221
   Web of Science ®Google Scholar
• Barros-SilvaJDLeitãoDAfonsoLAssociation of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patientsBr J Cancer20091003488493
   Web of Science ®Google Scholar
• BerxGBeckerKFHoflerHvan RoyFMutations of the human E-cadherin (CDH1) geneHum Mutat1998122262379744472
   PubMed Web of Science ®Google Scholar
• PedrazzaniCCorsoGMarrelliDRovielloFE-cadherin and hereditary diffuse gastric cancerSurgery2007142564565717981184
   PubMed Web of Science ®Google Scholar
• GarcíaIVizosoFMartínAClinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancerAnn Surg Onc2003103234241
   PubMed Web of Science ®Google Scholar
• NakajimaMSawadaHYamadaYThe prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomasCancer19998591894190210223227
   PubMed Web of Science ®Google Scholar
• UchinoSTsudaHMaruyamaKOverexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patientsCancer19937211317931847902202
   PubMed Web of Science ®Google Scholar
• MatsubaraJYamadaYNakajimaTEClinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancerOncology2008741–2768318544998
   PubMed Web of Science ®Google Scholar
• Cortes-FunesHRiveraFAlesIPhase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. In: 2007 ASCO annual meeting proceedings part IJ Clin Oncol20074613
   Google Scholar
• NicholasGCrippsCAuH-JEarly results of a trial of trastuzumab, cisplatin and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER2 In: ESMOAnn Oncol2006 Abstract 1105
   Google Scholar
• Bekaii-SaabTSRodaJMGuenterbergKDA phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignanciesMol Cancer Ther20098112983299119887543
   PubMed Web of Science ®Google Scholar
• SatohTLeonJLopezRIQuality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer2010 ASCO gastrointestinal cancer symposiumOrlando2010
   Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• AjaniJAMoiseyenkoVMTjulandinSClinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study GroupJ Clin Oncol200725223205320917664467
   PubMed Web of Science ®Google Scholar
• KornekGVRadererMSchollBEffective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancerBr J Cancer200286121858186312085176
   PubMed Web of Science ®Google Scholar
• EstevaFJValeroVBooserDPhase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerJ Clin Oncol20022071800180811919237
   PubMed Web of Science ®Google Scholar
• TedescoKLThorADJohnsonDHDocetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trialJ Clin Oncol20042261071107715020608
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• BaselgaJTripathyDMendelsohnJPhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Clin Oncol19961437377448622019
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• LuCHWysqomierskiSLTsengLMPreclinical testing of clinically applicable strategies of overcoming trastuzumab resistance by PTEN deficiencyClin Cancer Res200713195883588817908983
   PubMed Web of Science ®Google Scholar
• NahataRYuanLXZhangBInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res200565231111811112816322262
   PubMed Web of Science ®Google Scholar
• Price-SchiaviSAJepsonSLiPRat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism of herceptin resistanceInt J Cancer200299678379112115478
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcanaAExpression of p95HER2 receptor and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• FabiAMetroGFerrettiGDo HER2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systemic review of observational studiesBreast200817549950518450443
   PubMed Web of Science ®Google Scholar
• ExtraJ-MAntoineE-CVincent-SalomonAEfficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine studyOncologist201015879980920671105
   PubMed Web of Science ®Google Scholar
• Von MinckwitzGdu BoisASchmidtMTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 studyJ Clin Oncol200927121999200619289619
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2 positive advanced breast cancerN Eng J Med20063552627332743
   PubMed Web of Science ®Google Scholar
• SatohTBangYWangJInterim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancerJ Clin Oncol20102815s Abstract 4057
   Google Scholar
• CunninghamDAllumWHStenningSPPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Eng J Med200635511120
   PubMed Web of Science ®Google Scholar